{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infection+Prophylaxis&page=33",
    "query": {
      "condition": "Infection Prophylaxis",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 1280,
    "total_pages": 128,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infection+Prophylaxis&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infection+Prophylaxis&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T21:29:39.622Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03762772",
      "title": "Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hiv",
        "HSV"
      ],
      "interventions": [
        {
          "name": "TAF/EVG Vaginal Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CONRAD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2018-12-10",
      "completion_date": "2019-03-20",
      "has_results": false,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03762772"
    },
    {
      "nct_id": "NCT02615379",
      "title": "Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Instrumented Fusion",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Instrumented Spinal Fusion"
      ],
      "interventions": [
        {
          "name": "EPIFLO",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Neogenix, LLC dba Ogenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-07-01",
      "completion_date": "2019-03-31",
      "has_results": false,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02615379"
    },
    {
      "nct_id": "NCT00016068",
      "title": "Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "ganciclovir",
          "type": "DRUG"
        },
        {
          "name": "valganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2001-01",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2010-05-17",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Gainesville, Florida • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00016068"
    },
    {
      "nct_id": "NCT00507689",
      "title": "Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B Immunoglobulin (HBIg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-09",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2014-03-14",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00507689"
    },
    {
      "nct_id": "NCT00164580",
      "title": "Community Intervention Trial for Youth (CITY) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Community-Level Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "15 Years to 25 Years · Male only"
      },
      "enrollment_count": 12000,
      "start_date": "1996-10",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2012-09-27",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00164580"
    },
    {
      "nct_id": "NCT00473460",
      "title": "Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases",
        "Bronchitis, Chronic"
      ],
      "interventions": [
        {
          "name": "Avelox (Moxifloxacin, BAY12-8039)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 1404,
      "start_date": "2004-10",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473460"
    },
    {
      "nct_id": "NCT02842086",
      "title": "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis of HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5399,
      "start_date": "2016-09-02",
      "completion_date": "2026-07-29",
      "has_results": true,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 54,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02842086"
    },
    {
      "nct_id": "NCT03960970",
      "title": "Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometritis",
        "Cesarean Section; Infection",
        "Wound Infection"
      ],
      "interventions": [
        {
          "name": "Azithromycin 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Mefoxin 2g",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RWJ Barnabas Health at Jersey City Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 800,
      "start_date": "2019-09-15",
      "completion_date": "2020-11-30",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 1,
      "location_summary": "Jersey City, New Jersey",
      "locations": [
        {
          "city": "Jersey City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03960970"
    },
    {
      "nct_id": "NCT00603603",
      "title": "Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infection; Cesarean Section",
        "Surgical Wound Infection",
        "Endometritis"
      ],
      "interventions": [
        {
          "name": "80% inhaled oxygen via non-rebreather mask",
          "type": "OTHER"
        },
        {
          "name": "30% inhaled oxygen via nasal cannula",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 50 Years · Female only"
      },
      "enrollment_count": 606,
      "start_date": "2008-02",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603603"
    },
    {
      "nct_id": "NCT00345579",
      "title": "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Haemophilus Influenzae Type b",
        "Neisseria Meningitidis"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix/Infanrix Penta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 4432,
      "start_date": "2006-09",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-11-09T21:29:39.622Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345579"
    }
  ]
}